about   CII home   shop   checkout

Ultra-Sensitive Single-Molecule Array (Simoa) Technology for the Detection of Blood-Based Biomarkers in Neurology or Neurodegeneration



October 21, 2014
11 a.m. to 12:00 pm EDT

 

Sponsored by
Quanterix
 

Symposium Course Description :

Dr. Henrik Zetterberg (Sahlgrenska University) will provide an overview of the principles of the Simoa technology developed by Quanterix, Inc. Quanterix has developed the first total tau assay for blood and Dr. Zetterberg will discuss case studies of the use of this assay in mild traumatic brain injury and sport-related concussion.

In addition, he will describe the use of the Simoa technology for the development of a custom assay for neurofilament light chain (NFL) in blood. He will then describe the application of Simoa technology to other key neurological and neurodegenerative biomarkers.

Dr. Andreas Jeromin, Quanterix, will discuss the current status of development of blood-based biomarkers in central nervous system (CNS), and the importance of using blood-based biomarkers in CNS.

Learning Objectives:

To understand:

a.) The definition of CNS disorders

b.) Potential applications of Simoa technology in CNS – looking at total tau

c.) Current status of blood biomarker development in CNS

d.) Understand the Homebrew capabilities of the Simoa immunoassay analyzer

Speakers:

Dr. Andreas Jeromin, PhD.

Scientific and Medical Advisor
Quanterix Corporation

Andreas Jeromin, PhD, has established research programs in translational neuroscience in both industry and biotech for the last 15 years and co-authored more than 100 publications. He has also been elected a member of the Dana Alliance for Brain Initiatives. Andreas Jeromin has led biomarker qualification programs in diagnostics and therapeutics in acute neurological injury and neurodegeneration. This included several drug development programs from POC to a NINDS-supported phase III trial (Protect III). He also supports as member of the SABs or steering committee, several biomarker qualification efforts such as ADNI, the Coalition against Major Diseases (CAMD) directed by the Critical Path Institute (C-PATH), the Alzheimer's Association CSF QC and biomarker assay standardization initiatives in other CNS disorders, including MS (Accelerated Cure, ALS and PD. He is the founder and CSO of Atlantic Biomarkers, LLC, and joined Quanterix, Inc. as scientific and medical advisor in 2014.

Henrik Zetterberg M.D., Ph.D.

Head of the Department of Psychiatry and Neurochemistry
University of Gothenburg, Sweden

Henrik Zetterberg is Professor of neurochemistry at the Institute of Neurology at University College London, UK, Head of the Department of Psychiatry and Neurochemistry, University of Gothenburg, Sweden, and a senior consultant in clinical chemistry at Sahlgrenska University Hospital, Sweden. He obtained his medical degree and PhD at the University of Gothenburg in 2003. Zetterberg then undertook a postdoctoral fellowship at the Harvard Institutes of Medicine, USA, before returning to the University of Gothenburg where he was appointed Associate Professor of neurochemistry. He was a Fulbright Scholar and research fellow in neurology at the Harvard Institutes of Medicine, Boston between 2004 and 2005. Zetterberg’s research interests focus on brain function in health and disease with a particular emphasis on neurochemical markers.



Cost: No cost!



Download Webinar